Prostalund AB (FRA:7PL0) EPS without NRI: €-0.51 (TTM As of Sep. 2025)


FRA:7PL0 Prostalund AB FRA:7PL0
10 GF Score
Price €0.00
GF Value €0.02
! 6 Warning Signs
View Full Analysis

What is Prostalund AB EPS without NRI?

Prostalund AB FRA:7PL0 10 EPS without NRI is €-0.51 as of Sep. 2025. GuruFocus rates FRA:7PL0 with a GF Score™ of 10/100 and a GF Value™ of €0.02. The stock has 6 warning signs investors should review.

Prostalund AB's earnings per share without non-recurring items for the three months ended in Sep. 2025 was €-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.51.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -2.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Prostalund AB's EPS without NRI or its related term are showing as below:

FRA:7PL0' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -113.2   Med: 2.2   Max: 43.2
Current: -2.4

During the past 13 years, Prostalund AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 43.20% per year. The lowest was -113.20% per year. And the median was 2.20% per year.

FRA:7PL0's 3-Year EPS without NRI Growth Rate is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 11.6 vs FRA:7PL0: -2.40

Prostalund AB's EPS (Diluted) for the three months ended in Sep. 2025 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.51.

Prostalund AB's EPS (Basic) for the three months ended in Sep. 2025 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.51.


Prostalund AB  (FRA:7PL0) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Prostalund AB EPS without NRI Related Terms


Prostalund AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Prostalund AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostalund AB EPS without NRI Chart

Prostalund AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.00 -0.63 -0.73 -0.89 -0.60

Prostalund AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.21 -0.13 -0.16 -0.01

FRA:7PL0 vs HCA, THC, UHS: EPS without NRI Comparison

For the Medical Care Facilities subindustry, Prostalund AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostalund AB PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Prostalund AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Prostalund AB's PE Ratio without NRI falls into.


FRA:7PL0
10GF Score
Prostalund AB FRA:7PL0
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostalund AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.51 mean?
Prostalund AB (FRA:7PL0) has a EPS without NRI of €-0.51 as of Sep. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Prostalund AB and its competitors.
Is Prostalund AB's EPS without NRI too high?
Prostalund AB's current EPS without NRI is €-0.51. Overall, Prostalund AB has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Prostalund AB's EPS without NRI compare to HCA and THC?
Prostalund AB's EPS without NRI of €-0.51 can be compared against companies in the Healthcare Providers & Services industry. The industry median EPS without NRI is 11.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.60, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Prostalund AB and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostalund AB's current EPS without NRI is €-0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostalund AB stock overvalued right now?
Prostalund AB (FRA:7PL0) has a current EPS without NRI of €-0.51. The stock's GF Value™ is €0.02, compared to a current price of €0.00 — trading 97.5% below its estimated fair value. The current EPS without NRI is €-0.51. Prostalund AB's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Prostalund AB (FRA:7PL0), the current EPS without NRI is €-0.51 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostalund AB (FRA:7PL0) Overvalued in 2026?

Based on GuruFocus' analysis, Prostalund AB stock appears to be undervalued. The current stock price of €0.00 is trading 97.5% below its estimated GF Value™ of €0.02.

Key valuation signals for FRA:7PL0:

  • EPS without NRI: €-0.51
  • GF Value™: €0.02 vs. price of €0.00 (97.5% below fair value)
  • GF Score™: 10/100 with 6 warning signs

No single metric tells the full story. See the FRA:7PL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prostalund AB Business Description

Address Scheelevagen 19, Lund, SWE, SE-223 63
Prostalund AB develops, markets and sells urological products. The Company has a treatment concept (CoreTherm Concept) for personalized heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50. It has developed a new platform, CoreTherm Eagle which includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians.
10GF Score

Get the complete analysis for FRA:7PL0

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price
€0.02
GF Value